中國生物製藥(01177.HK)旗下肝癌治療藥物"甲磺酸侖伐替尼膠囊"獲批上市
格隆匯7月26日丨中國生物製藥(01177.HK)宣佈,集團開發的肝癌治療藥物"甲磺酸侖伐替尼膠囊"(商品名:福凱特)已獲中國國家藥品監督管理局頒發藥品註冊證書。該產品按化學藥品4類申報,視同通過仿製藥質量和療效一致性評價,同品種國內首家仿製藥獲批。適應症為:用於既往未接受過全身系統治療的不可切除的肝細胞癌患者的治療。
侖伐替尼是多種酪氨酸激酶受體 (RTK) 抑制劑,可抑制血管內皮生長因子 (VEGF) 受 體VEGFR1(FLT1)、VEGFR2(KDR)和VEGFR3(FLT4)的激酶活性,對成纖維細胞生長因子受體(FGFR)、血小板衍生生長因子受體(PDGFR)、幹細胞因子受體KIT和RET融合基因也有抑制作用,從而抑制腫瘤血管的生成及腫瘤進展。甲磺酸侖伐替尼是近十年來肝癌一線靶向治療領域III期臨牀研究唯一獲得陽性結果的藥物。臨牀資料顯示,與全球總人羣相比,甲磺酸侖伐替尼在中國患者亞羣中的療效尤其顯著。甲磺酸侖伐替尼在中國、日本、美國等國家均已被納為治療中晚期肝癌的一線藥物。
據統計,中國每年新發肝癌病人46.6萬,佔全球發病量一半以上(資料引自:Cancer Statistics inChina, 2015)。目前國內市場甲磺酸侖伐替尼膠囊僅有原研藥在售,市場空間廣闊。集團開發的甲磺酸侖伐替尼膠囊獲批上市,將進一步完善集團抗腫瘤產品線佈局,並有助減輕國內肝癌患者的經濟負擔。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.